Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19

Mostrar otras versiones (1)

BACKGROUND: Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvanitis, Panos, Lerner, Alexis Hope, Vieira, Kendra, Almaghlouth, Nouf, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882636/
https://www.ncbi.nlm.nih.gov/pubmed/36711556
http://dx.doi.org/10.21203/rs.3.rs-2433445/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882636/
https://www.ncbi.nlm.nih.gov/pubmed/36711556
http://dx.doi.org/10.21203/rs.3.rs-2433445/v1

Ejemplares similares